key: cord-0719692-z4skpmd5 authors: Laffey, J.G.; Chikhani, M.; Bates, D.G.; Hardman, J.G. title: Supporting more than one patient with a single mechanical ventilator: useful last resort or unjustifiable risk? date: 2020-06-01 journal: Br J Anaesth DOI: 10.1016/j.bja.2020.05.029 sha: 5a573d21524659733624d138d997327de9b26394 doc_id: 719692 cord_uid: z4skpmd5 nan The coronavirus disease 2019 (COVID-19) causes diffuse lung inflammation and injury that can worsen rapidly into acute hypoxaemic respiratory failure (AHRF) and acute respiratory distress syndrome (ARDS). At the time of writing, more than 4.4 million people globally have been confirmed to have had COVID-19, 1 with the USA alone exceeding 1.4 million cases. Spain, Italy, Germany, France, China and the UK have also been severely affected, and the global deaths have exceeded 300,000. 1 Some projections suggest that up to 60% of the global population will contract COVID-19 over the coming months. 2 While about 80% of people who contract COVID-19 will have a mild (or asymptomatic) course, a minority (~ 10%) have symptoms of sufficient severity to require hospitalisation, and ~ 25% of hospitalised patients will require positive pressure mechanical pulmonary ventilation. In patients requiring mechanical ventilation, the median duration of ventilation is 6 days, although it should be noted that this figure includes those who die, such that the figure for those surviving to discharge is necessarily greater. 3 This enormous global disease burden has resulted in a massive demand for mechanical ventilatory support (and the equipment required to provide it). In some tragic situations, doctors have been obliged to choose which patients should receive ventilatory support (and who should not). 4 While these situations are likely to be rare, they have happened and will continue to occur. This obliges healthcare professionals to make treatment allocation decisions based on equipment availability, rather than what is in the best interest of each individual patient. In the developed world, this is a novel (and disturbing) scenario with significant ethical implications. 4a The fabrication of ventilators is rapidly scaling up worldwide, and there have been various reports of industries in quite disparate fields repurposing their design and production resources to supplement the supply of ventilators. However, even relatively simple ventilators are highly specialized items of equipment and it is likely that the design, testing, manufacture and certification of suitable equipment will be inadequate in the time available during this pandemic. Other solutions to the problem of a lack of mechanical ventilators are likely to be needed. Projections of the likely extent of the requirement for mechanical ventilatory support during the COVID pandemic, coupled with reports of situations in which ventilator requirement has exceeded supply, has prompted reconsideration of the idea of using a single ventilator to ventilate the lungs of more than one patient. 5 This is not a new idea. There have been various reports of ventilators being used to ventilate more than one patient during mass casualty situations, 6 and reports of testing the technology on mechanical 'test' lungs 7 and sheep. 8 Approaches have included simple splitting of the inspiratory and expiratory outlets from the ventilator and connecting two or more sets of tubing in parallel. The use of a single ventilator to simultaneously provide ventilatory support to more than one patient could permit rapid upscaling of ventilator capacity at this time of crisis. Furthermore, given that other (perhaps even more dangerous) pandemics are likely to occur in the future, this potential mechanism of upscaling ventilatory equipment is worthy of consideration. There are several relatively simple solutions that could enable a mechanical ventilator to support two (or more) patients. 5, 9, 10 In most of these suggested solutions, there is no capacity to safely and effectively control the ventilatory parameters for each patient. Pressure-controlled ventilation is generally used, with identical inspiratory and expiratory pressures, inspired oxygen fraction (FiO 2 ), positive end-expiratory pressure (PEEP), inspiratory to expiratory (I:E) ratio, respiratory rate (RR) being delivered to both patients. Consequently, the distribution of tidal volume between the two or more patients is dependent on the characteristics of each patients' lungs (i.e. inspiratory and expiratory resistances and thoracic compliance). Pressure-controlled modes are most safely implemented because changes in the compliance and/or resistance of one patient's chest will have a smaller effect on the tidal volume delivered to the other patient when a fixed inflation pressure is provided. In contrast, in volume-controlled modes, any inspired volume not delivered to one patient will be redirected to the more compliant chest (or that with lower inspiratory resistance); this risks dangerous hyperinflation and barotrauma or volutrauma in the event of a sudden change in the characteristics of one patient (e.g. mucous plug, coughing or kinked tracheal or circuit tube). Basic splitting approaches may be sufficient in the short term, where intense supervision is available and where ventilatory requirements are similar in both patients, and where the same ventilatory settings can be used relatively safely for both patients. However, in COVID-19 patients ventilatory requirements can be quite disparate between patients, and also can evolve over time. 11, 12 This substantially increases the requirement for very sophisticated splitting arrangements, or for intensive vigilance, usually in the face of limitations on the availability of qualified clinicians, in order to provide appropriate adjustments of the ventilator settings and other characteristics of the splitting applied. Where changes in compliance and/or resistance occur, there can be rapid and substantial alteration in the tidal volume delivered to the other patient(s). In the context of the severe ventilation-perfusion (VQ) mismatch and PaCO 2 dependency shown by COVID-19 patients (where an increase in P A CO 2 can significantly reduce P A O 2 , and thus worsen an already perilous PaO 2 ), such changes in delivered ventilation could be rapidly and severely detrimental to the patient, particularly if individual tidal volumes are not continually observed. In the scenario of thoracic compliance and/or resistance mismatch between the two or more patients sharing a ventilator, the only simple way to increase tidal volume to the more severely lung-injured patient is to increase inspiratory pressure (resulting in the other patient receiving a larger than desired tidal volume), or to fit a pressure reducing valve or flow restrictor to the other patient's inspiratory limb. However, with increasing complexity comes an increasing risk of errors, mechanical failure and consequent patient harm. Other clear limitations of ventilator splitting include the inability to discretely vary FiO 2 , PEEP and I:E ratio between patients, reducing the options for fine-tuning ventilation parameters, which have been shown to be of importance in treating COVID-19 patients. 8, 9 Spontaneous breathing presents another problem, in that in the absence of sophisticated compensatory mechanics spontaneous inhalation risks reducing the volume delivered to the other patient. Consequently, deep sedation, possibly with muscle paralysis, is likely to be required in the setting of shared ventilation. Medical device companies and engineering consortia are currently attempting to produce the necessary hardware to allow the ventilation of more than one patient using a single ventilator. In the USA, Prisma Health (location) has designed a simple ventilator expansion device produced using 3D printing technology from material that allows for appropriate filtering of bacteria and viruses in the ventilator tubing. The VESper TM splitter can be produced at minimal cost, and Ethicon Inc. (location) is manufacturing and distributing the VESper at no cost to healthcare providers in the US under emergency use authorisation (EUA by the US FDA)Food and Drug Administration to address the COVID-19 health emergency. 13 Ongoing developments of ventilator splitter technology currently being implemented include the addition of one-way valves to ensure that expire gas from one patient's exhalation cannot reach the other, and the addition of flow meters in each patient's inspiratory tubing to monitor and adjust individualized tidal volume. Low-cost monitoring solutions that provide individualized monitoring of patient flows and volumes have been developed (ref). Additional engineering solutions being considered include configurable pressure-reducing valves on expiratory limbs to provide individually configurable PEEP, air entrainment devices to allow individually modifiable FiO 2 , and adjustable flow restrictors to compensate for disparate inspiratory resistance. Coping with spontaneous breathing in a split ventilation configuration is complex, but sophisticated engineering solutions are certainly feasible, although it is likely that they will require complex and reactive technology that exceeds simple adaptations available in a crisis. Consideration of the place and likely utility of each of these is beyond the scope of this article. There are currently few substantive guidelines to assist clinicians in deciding which patients might be selected to share a single ventilator (beyond patient weight); examples include the US COVID-19 co-ventilation task force, 14 but the complexity and sensitivity of the decisionmaking here is challenging and complex. 4a Intuitively, patients sharing a ventilator should have similar a oxygen requirement and thoracic compliance, but beyond this there is little expertise or evidence base besides the cohorting of COVID-19 patients by disease stage or disease 'phenotype'. Previous experience in the treatment of ARDS has highlighted the fact that patients with similar disease presentation (PaO 2 /F I O 2 ratios, etc.) may have very different underlying pathophysiology, requiring quite different ventilator settings for appropriate management. Computational simulators that include high-fidelity mechanistic representations of integrated organ-systems in individual patients could be a useful tool for investigating which patient parameters are most appropriate for selecting patients for shared ventilation. The additional complexity brought by sharing a ventilator between patients, along with the additional risk, mandates additional training, staffing and monitoring. For example, the interpretation of a high-or low-pressure alarm on the ventilator presents a substantially more complex task to the supervising clinician when two patients are sharing a ventilator. Clinical experience is minimal in this scenario, and care can no longer be considered 'routine' (i.e. based upon proven protocols); instead, it will require frequent, active problem-solving, which is likely to be disproportionally more cognitively and emotionally demanding than managing a single ventilated patient. It is thus clear that provision of shared ventilation is not merely a matter of finding an engineering solution, but it will also bring substantial challenges in clinical decision-making, training, supporting staff, and in safeguarding patients in the context of a novel and poorly-trialled technology. Rather than considering shared ventilation as a technical problem whose solution provides an additional needed resource, we must consider the potential gains and losses of implementing such technology. In the situation where demand exceeds supply (i.e. not enough ventilators), one might expect that the lack of a ventilator immediately and inevitably increases the risk of death. However, there are other therapies available to support patients with hypoxaemic respiratory failure (including, but not limited to, continuous positive airway pressure [CPAP] and use of low-fidelity ventilation). It is not currently clear that mechanical ventilation brings a substantial survival benefit in COVID-19; indeed, some sources are reporting mortality rates over 80% in patients with COVID-19 who receive mechanical ventilation. 15 We must also consider that shared ventilation will inevitably reduce the fidelity (and thus likely benefit) of the ventilation that would have been provided to a single patient (with their own ventilator), creating another ethical dilemma. 16 Thus, the decision to share a ventilator does not bring the same benefit as an additional ventilator would have brought. In that scenario, it might be argued that in many cases the 'net gain' (i.e. expected numbers surviving) might be greater if one patient receives (non-shared) mechanical ventilation, while the other receives alternative support (e.g. CPAP). Finally, there is of course, another alternative to sharing mechanical ventilation: increasing the availability of mechanical ventilators. Efforts to upscale ventilator production, coupled with redeployment of ventilators around the world to meet local demand, might offer a more effective solution to a respiratory crisis such as COVID-19. However, the unfortunate likelihood of future unpredictable mass casualty situations, together with the potentially dramatic effects of pandemics on developing countries without adequate healthcare systems, means that further investigation of this option as a last resort is still likely to be needed. JGH is the associate editor-in-chief of the British Journal of Anaesthesia. The other authors have no conflicts to declare. Facing Covid-19 in Italy -Ethics, Logistics, and Therapeutics on the Epidemic's Front Line An ethical algorithm for rationing life sustaining treatment during the COVID-19 pandemic Use of a single ventilator to support 4 patients: laboratory evaluation of a limited concept Increasing ventilator surge capacity in disasters: ventilation of four adult-human-sized sheep on a single ventilator with a modified circuit A Single Ventilator for Multiple Simulated Patients to Meet Disaster Surge Simultaneous ventilation of two healthy subjects with a single ventilator COVID-19 pneumonia: different respiratory treatment for different phenotypes?